Phase II Study of Skin Toxicity Dosing of IRESSA (Gefitinib) in Squamous Cell Carcinoma of the Head and Neck
Status:
Completed
Trial end date:
2013-05-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to demonstrate the activity (response rate and rate of stable
disease) of Iressa administered as a single agent escalated to a dose that produces grade 2
skin toxicity in patients with recurrent and/or metastatic squamous cell carcinoma of the
head and neck (SCCHN).